Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib vs tocilizumab with methotrexate in MTX-inadequate responders with moderate-to-severe rheumatoid arthritis
ChiCTR2500104153Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Dalian Medical University
- Start
- Jun 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of upadacitinib and tocilizumab in rheumatoid arthritis (RA) (2 arms), sponsored by The Second Affiliated Hospital of Dalian Medical University. Primary endpoint: ACR20. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
upadacitinibtocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ChiCTR2500104153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104153.